|Application / Reactivity||Rat (Rattus)|
|Functional Studies (Func)||1 Antibodies|
|Immunochromatography (IC)||1 Antibodies|
|Immunocytochemistry (ICC)||1 Antibodies|
|Immunohistochemistry (IHC)||1 Antibodies|
|Immunohistochemistry (Frozen Sections) (IHC (fro))||2 Antibodies|
|Immunohistochemistry (Paraffin-embedded Sections) (IHC (p))||1 Antibodies|
|Western Blotting (WB)||6 Antibodies|
|Antigen||Complement Decay-Accelerating Factor (CD55) Antibodies|
|Reactivity||Rat (Rattus) Alternatives|
|Conjugate||This CD55 antibody is un-conjugated Alternatives|
Functional Studies (Func), Western Blotting (WB)
|5 references available|
|Supplier||Log in to see|
Product Details anti-CD55 AntibodyTarget Details CD55 Application Details Handling References for anti-CD55 Antibody (ABIN2192123) Images
|Sterility||0.2 μm filtered|
Target Details CD55Product Details anti-CD55 Antibody Application Details Handling References for anti-CD55 Antibody (ABIN2192123) Images back to top
|Alternative Name||Complement Decay Accelerating Factor (CD55 Antibody Abstract)|
|Background||The monoclonal antibody RDIII-7 recognizes complement decay accelerating factor (DAF), also designated as CD55. RDIII-7 recognizes the common extracellular SCR region of CD55, detecting all isoforms of the protein. Cells express on their surface several proteins which protect against complement attack, namely C receptor I (CR1), decay accelerating factor (DAF), membrane cofactor protein (MCP) and CD59. CR1, DAF and MCP regulate the activation pathways of complement by either accelerating decay of the C3 and C5 convertase (CR1, DAF), or acting as cofactors for the serine protease factor I, which cleaves and irreversibly inactivates C3b (CR1, MCP). Rat DAF (CD55) is a 60 kDa transmembrane protein that binds C3b and C4b to inhibit formation and half- life of the C3 convertases. It belongs to the receptors of complement activation (RCA) family. DAF is broadly distributed among cells in contact with plasma complment proteins, including both haematopoietic and nonhaematopoietic cells. Although DAF does not have an essential role in controlling hemolysis of erythrocytes, it has an important role in regulation of the deposition of C3 on nucleated cells. Together with other complement regulators DAF protects self cells from autologous complement- mediated injury. DAF cooperates with CD46 in circumventing autologous C3 deposition, while CD59 inhibits the pathway at the critical end-point. Aliases DAF, CD55 Immunogen NIH-3T3 cells expressing GPI-anchored rat DAF|
Application DetailsProduct Details anti-CD55 Antibody Target Details CD55 Handling References for anti-CD55 Antibody (ABIN2192123) Images back to top
|Application Notes||For immunohistology, flow cytometry and Western blotting, dilutions to be used depend on detection system applied. It is recommended that users test the reagent and determine their own optimal dilutions. The typical starting working dilution is 1:50. For functional studies, in vitro dilutions have to be optimized in user's experimental setting.|
|Restrictions||For Research Use only|
HandlingProduct Details anti-CD55 Antibody Target Details CD55 Application Details References for anti-CD55 Antibody (ABIN2192123) Images back to top
|Buffer||PBS, containing 0.1 % bovine serum albumin.|
|Storage Comment||Product should be stored at 4 °C Under recommended storage conditions, product is stable for one year.|
|Expiry Date||12 months|
References for anti-CD55 Antibody (ABIN2192123)Product Details anti-CD55 Antibody Target Details CD55 Application Details Handling Images back to top
|Product cited in:||
Mizuno, Donev, Harris et al.: "CD55 in rat male reproductive tissue: differential expression in testis and expression of a unique truncated isoform on spermatozoa." in: Molecular immunology, Vol. 44, Issue 7, pp. 1613-22, 2006 (PubMed).
Mizuno, Harris, Morgan: "Spermatogenic cells distal to the blood-testis barrier in rats lack C3 convertase regulators and may be at risk of complement-mediated injury." in: Journal of reproductive immunology, Vol. 69, Issue 1, pp. 23-34, 2006 (PubMed).
Harris, Williams, Linton et al.: "Coupling complement regulators to immunoglobulin domains generates effective anti-complement reagents with extended half-life in vivo." in: Clinical and experimental immunology, Vol. 129, Issue 2, pp. 198-207, 2002 (PubMed).
Harris, Spiller, Morgan: "Human and rodent decay-accelerating factors (CD55) are not species restricted in their complement-inhibiting activities." in: Immunology, Vol. 100, Issue 4, pp. 462-70, 2000 (PubMed).
Spiller, Harris, Morgan: "Efficient generation of monoclonal antibodies against surface-expressed proteins by hyperexpression in rodent cells." in: Journal of immunological methods, Vol. 224, Issue 1-2, pp. 51-60, 1999 (PubMed).